SystImmune Inc. Report issue

For profit Phase 1
Founded: Richmond WA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04603287
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

SystImmune Inc.

Active Ingredients

Drugs in Phase 1 Trials (6)

gnc-035 (2 trials)

gnc-038 (1 trial)

gnc-039 (1 trial)

si-b001 (1 trial)

si-b003 (1 trial)

si-f019 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Glandular and Epithelial (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 7
  • # of Trial APIs: 6